Product
EU-Ocrevus
1 clinical trial
1 indication
Indication
Relapsing-remitting multiple sclerosisClinical trial
A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 1/3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple SclerosisStatus: Not yet recruiting, Estimated PCD: 2027-02-01